Literature DB >> 31955863

The role of elevated high-sensitivity cardiac troponin on outcomes following severe blunt chest trauma.

Triinu Keskpaik1, Joel Starkopf2, Ülle Kirsimägi3, Vladislav Mihnovitš4, Andrus Lomp5, Eeva-Maarja Raamat6, Sten Saar7, Peep Talving8.   

Abstract

BACKGROUND: Blunt cardiac injuries (BCI) result in poor outcomes following chest trauma. Admission ECG and troponin levels are frequently obtained in patients with suspected BCI, nevertheless, the prognostic value of cardiac troponins remains controversial. The purpose of the current study was to review the prognostic value of elevated high-sensitivity cardiac troponin T (hs-cTnT) in patients with severe blunt chest injuries. We hypothesized that elevated hs-cTnT result in poor outcomes in this subgroup of severe trauma patients.
METHODS: After IRB approval, all consecutive patients with Injury Severity Score (ISS) > 15 and chest Abbreviated Injury Scale (AIS) score ≥3 admitted to the major trauma centers between 1/2015 and 6/2017 were retrospectively reviewed. Primary outcomes were in-hospital and one-year mortality. Secondary outcomes included ventilator days and Glasgow Outcome Scale (GOS) score at hospital discharge.
RESULTS: Overall, 147 patients were included. Mean age was 49.0 (19.1) years and 75% were male. Serum troponin levels on admission were accrued in 82 (56%) patients with elevated and normal hs-cTnT levels found in 54 (66%) and in 28 (34%) patients, respectively. Elevated hs-cTnT group had significantly higher ISS and lactate level, and lower systolic blood pressure on admission. In-hospital mortality was significantly higher in patients with elevated hs-cTnT levels compared to patients with normal hs-cTnT levels (26% vs. 4%, p = 0.02). Hs-cTnT level > 14 ng/L was significantly associated with extended ventilator days and lower GOS score at hospital discharge.
CONCLUSION: Blunt chest trauma victims with elevated hs-cTnT levels experience significantly poorer adjusted outcomes compared to patients with normal levels. Compliance with EAST practice management guidelines following severe blunt chest trauma was not fully complied in our study cohort that warrants prospective performance improvement measures.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Blunt cardiac injury; Chest trauma; High-sensitivity cardiac troponin

Mesh:

Substances:

Year:  2019        PMID: 31955863     DOI: 10.1016/j.injury.2019.12.037

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  6 in total

1.  Changes and significance of serum troponin in trauma patients: A retrospective study in a level I trauma center.

Authors:  Li-Wen Dou; Zhe Du; Ji-Hong Zhu; Tian-Bing Wang
Journal:  World J Emerg Med       Date:  2022

2.  Associations between elevated high-sensitive cardiac troponin t and outcomes in patients with acute abdominal pain.

Authors:  Triinu Keskpaik; Peep Talving; Ülle Kirsimägi; Vladislav Mihnovitš; Anni Ruul; Toomas Marandi; Joel Starkopf
Journal:  Eur J Trauma Emerg Surg       Date:  2022-07-20       Impact factor: 2.374

3.  Management of Thoracic and Cardiac Trauma: A Case Series and Literature Review.

Authors:  Akshay Kumar; Nimisha Shiwalkar; Sameer Bhate; Suresh Keshavamurthy
Journal:  Cureus       Date:  2022-06-30

Review 4.  Cardiac injury following blunt chest trauma: diagnosis, management, and uncertainty.

Authors:  Saeed Shoar; Fatemeh Sadat Hosseini; Mohammad Naderan; Siamak Khavandi; Elsa Tabibzadeh; Soheila Khavandi; Nasrin Shoar
Journal:  Int J Burns Trauma       Date:  2021-04-15

5.  Incidence and prognosis of myocardial injury in patients with severe trauma.

Authors:  Alexandra Stroda; Simon Thelen; René M'Pembele; Antony Adelowo; Carina Jaekel; Erik Schiffner; Dan Bieler; Michael Bernhard; Ragnar Huhn; Giovanna Lurati Buse; Sebastian Roth
Journal:  Eur J Trauma Emerg Surg       Date:  2021-12-08       Impact factor: 2.374

Review 6.  Trauma-Induced Coagulopathy: Overview of an Emerging Medical Problem from Pathophysiology to Outcomes.

Authors:  Gabriele Savioli; Iride Francesca Ceresa; Luca Caneva; Sebastiano Gerosa; Giovanni Ricevuti
Journal:  Medicines (Basel)       Date:  2021-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.